RIMAN
July 2, 2024
RIMAN Korea, the South Korean skincare direct seller behind the Incellderm brand, said its overseas business has reached roughly 96.3 billion won in cumulative sales in North America since it opened its first foreign subsidiary in the United States in October 2022.
The company said growth accelerated from the second half of 2023, and that in April 2024 sales in the United States and Canada alone reached 9.8 billion won for the month. At that pace, RIMAN expects its full North American business to top about 120 billion won in 2024.
RIMAN set up a local branch in Taiwan in December 2023 and said that market generated 26.9 billion won in cumulative sales in its first five months. The company planned to open a Hong Kong subsidiary in July 2024, which it described as a springboard for expansion into Southeast Asia.
RIMAN credited a localization strategy for the results, saying most of its overseas sellers and customers are local residents rather than Korean expatriates and that local staff lead marketing in its foreign branches. A company official said the goal for 2024 was for global sales to overtake domestic sales.
Founded in South Korea in 2018, RIMAN sells skincare, personal care and wellness products, including the Incellderm, Botalab and Lifening brands.